Kratom living monograph
Product-specific harm reduction without safety promises or dosing advice.
Harm reduction
Harm reduction does not make kratom safe. The largest levers are product clarity, avoiding depressant combinations, allowing time rather than redosing quickly, and responding early to dependence signs.
Treat leaf/powder, tea, extracts, and 7-OH products separately. Do not transfer leaf gram values to extracts; assume high uncertainty when labelling is unclear.
Journal of AOAC International, 2026Bundesinstitut für Risikobewertung (BfR), 2025Do not combine with opioids, benzodiazepines/Z-drugs, alcohol, GHB/GBL, gabapentinoids, or other strongly sedating agents. Staggered use can still overlap because elimination is prolonged.
WHO Expert Committee on Drug Dependence, 2021Pharmaceutics, 2022Onset and plasma peaks can be delayed. Early redosing increases the risk of unexpectedly high total exposure.
Pharmaceutics, 2022Molecules, 2024With an unknown product, new batch, after a break, during illness, or with additional medication, a sober person should be reachable and know emergency signs.
Bundesinstitut für Risikobewertung (BfR), 2025National Institute on Drug Abuse (NIDA), 2025Drowsiness, dizziness, nausea, and after-effects can impair reaction and judgement. Do not drive or operate machinery.
Bundesinstitut für Risikobewertung (BfR), 2025National Center for Complementary and Integrative Health, 2025Record product, timing, frequency, adverse effects, and withdrawal symptoms. Increasing frequency or using merely to feel “normal” are early warning signs.
Drug and Alcohol Dependence, 2014Journal of Psychoactive Drugs, 2019With jaundice, dark urine, pale stool, severe itching, or persistent right upper abdominal pain, stop kratom and seek prompt medical assessment.
Drug and Alcohol Dependence, 2021Journal of Addiction Medicine, 2026Daily use is not a moral failure. It is a practical signal to review tolerance, withdrawal, product strength, and co-use in a structured way.
Synapedia offers orientation but does not replace medical diagnosis or treatment.
Call 112 immediately, check breathing, do not leave the person alone, and follow dispatcher instructions. If breathing, use the recovery position; if not breathing normally, start resuscitation as directed.
For an opioid-type emergency, naloxone may be used if available and the responder knows how. Case reports describe improvement after naloxone, but response in kratom toxicity is not guaranteed. Naloxone never replaces calling 112 or ventilation/resuscitation and cannot reverse every co-ingestant hazard.
National Capital Poison Center, 2025Journal of Medical Toxicology, 2019Cureus, 2023Trust
Each source is tied to a claim domain. “Reviewed” means editorial source review—not individual medical clearance.
Bundesinstitut für Risikobewertung (BfR) · 2025
Contributes: German risk communication on products, adverse effects, and classification.
Limit: Regulatory assessment; emphasises limited evidence and is not a product-specific legal ruling.
WHO Expert Committee on Drug Dependence · 2021
Contributes: Broad international review of pharmacology, toxicity, dependence, and case reports.
Limit: Many severe cases are confounded by co-use and heterogeneous products.
Contributes: Research-based overview of effects, products, dependence, and uncertainties.
Limit: Secondary government overview, not an individual primary study.
Contributes: Government overview of benefit claims, adverse effects, and research limits.
Limit: Secondary source; not product-specific.
ACS Central Science · 2019
Contributes: Preclinical data on 7-OH formation, potency, and opioid activity.
Limit: Animal, cellular, and ex-vivo evidence; not a direct clinical dosing basis.
Drug and Alcohol Dependence · 2014
Contributes: Observational data from 293 regular users on dependence and withdrawal.
Limit: Regional, non-randomised self-report sample in a traditional-use context.
Contributes: Systematic review and case series on clinical withdrawal presentations.
Limit: Small heterogeneous case literature with publication bias; no standard withdrawal trajectory.
Drug and Alcohol Dependence · 2021
Contributes: Well-characterised cases of clinically significant kratom-associated liver injury.
Limit: Case series without incidence estimate; product composition not always fully known.
Contributes: Current systematic synthesis of published liver-injury cases.
Limit: Case-report literature cannot quantify frequency or individual risk.
Phytochemistry · 2026
Contributes: Current analytical evidence on variability across commercial products.
Limit: Product sample does not represent the entire rapidly changing market.
Journal of AOAC International · 2026
Contributes: Analytical study identifies highly enriched 7-OH products with non-leaf-like profiles.
Limit: Market sample; chemical analysis does not directly quantify clinical event rates.
Contributes: Toxicology emergency guidance, including naloxone when a person is not breathing.
Limit: US emergency context; does not replace German emergency services or clinical evidence.
Contributes: Case report of clinical improvement after naloxone.
Limit: Single case; does not establish typical effectiveness or product safety.
